{{Infobox company
|name = Meda AB
|image = Meda AB logo.svg
|trading_name = OTCPK:MDABY
|location_city = [[Solna]]
|location_country = Sweden
|revenue = >{{currency|15 billion|SEK}} (2014)
|num_employees = 5,202 (2014)
}}
'''Meda AB''' is a [[Pharmaceutical drug|specialty pharmaceutical]] company, headquartered in [[Solna]], [[Sweden]]. At the end of 2014, Meda had 5,202 employees.  Meda's pharmaceuticals are sold in more than 150 countries.<ref>{{cite web|title = About Meda|url = http://www.meda.se/about-meda/|accessdate = 15 August 2015|publisher = Meda AB}}{{Self-published inline|date = August 2015|certain = yes}}</ref>

Meda was listed on the [[Stockholm Stock Exchange|Stockholm stock market]] until it was acquired by [[Mylan]] in 2016 through a cash and stock offer.

==Mergers, acquisitions and divestments==
In 2014, Meda acquired the Italian firm RottaPharm Madaus in order to add consumer health products to their portfolio.<ref name=":0">{{Cite news|url = https://www.bloomberg.com/news/articles/2015-08-27/swedish-drugmaker-meda-said-to-explore-sale-of-u-s-operations|title = Swedish Drugmaker Meda Said to Weigh Sale of U.S. Operations|last = Ewing|first = Adam|date = 27 August 2015|access-date = 28 August 2015|last2 = Baigorri|first2 = Manuel|agency = Bloomberg Business}}</ref>  Meda explored in 2015 the possibility of divesting its United States division, Meda Pharmaceuticals, to raise funds for expansion in other areas.<ref name=":0" />{{clade
|label1=Meda
|1={{clade
  |label1=
  |1={{clade
    |label1=acquired
    |1=Rottapharm Madaus (2014)
    |label2=plans to divest
    |2=Meda Pharmaceuticals (2015)
    }}
  }}
}}

==References==
{{Reflist}}

[[Category:Pharmaceutical companies of Sweden]]
[[Category:2016 acquisitions]]